Drug intelligence / Profile preview

metoprolol succinate + metoprolol

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Metoprolol succinate + metoprolol refers to a combination or sequential use of two salt forms of the cardioselective beta-1 adrenergic receptor blocker metoprolol. Metoprolol succinate is an extended-release formulation (marketed as Toprol-XL) designed for once-daily administration, primarily indicated for hypertension, angina pectoris, and stable heart failure. Metoprolol (typically administered as the tartrate salt, marketed as Lopressor) is an immediate-release formulation used for hypertension, angina, and the acute management of myocardial infarction. Metoprolol works by competitively antagonizing beta-1 adrenergic receptors in cardiac tissue, which reduces heart rate, cardiac contractility, and blood pressure, thereby decreasing myocardial oxygen demand and providing cardioprotective benefits. This combination is often discussed in clinical contexts regarding the transition from acute immediate-release or intravenous therapy to long-term maintenance with extended-release formulations.

Brand names
Toprol-XLLopressor
Other names
metoprolol succinate and metoprolol tartratemetoprolol succinate/metoprolol tartrate
02

Targets

ADRB1 (β1)ADRB3 (β3)ADRB2 (β2)

Beyond the preview

Go deeper on metoprolol succinate + metoprolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metoprolol succinate + metoprolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call